Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Case Reports in Oncology|June 29, 2023
Durable Response to Maintenance Treatment Comprised of Viagenpumatucel-L, Nivolumab, Ramucirumab, and Docetaxel in a PD-L1-Low Advanced-Stage Non-Small-Cell Lung Cancer: A Case ReportRussell Gollard, Bill Arana, Erin Kaltenbrun, et al.Scientific Reports|December 18, 2020
Expression of transgenes enriched in rare codons is enhanced by the MAPK pathwayJackson Peterson, Siqi Li, Erin Kaltenbrun, et al.Birth Defects Research. Part A, Clinical and Molecular Teratology|May 4, 2011
Xenopus: An emerging model for studying congenital heart diseaseErin Kaltenbrun, Panna Tandon, Nirav M Amin, et al.Methods in Molecular Biology (Clifton, N.J.)|September 8, 2012
Immunoisolation of protein complexes from XenopusFrank L Conlon, Yana Miteva, Erin Kaltenbrun, et al.Plos Genetics|September 26, 2017
Formation of a TBX20-CASZ1 protein complex is protective against dilated cardiomyopathy and critical for cardiac homeostasisLeslie Kennedy, Erin Kaltenbrun, Todd M Greco, et al.The Journal of Clinical Investigation|December 2, 2014
Rare codons capacitate Kras-driven de novo tumorigenesisNicole L K Pershing, Benjamin L Lampson, Jason A Belsky, et al.Journal of Proteome Research|September 13, 2013
A Gro/TLE-NuRD corepressor complex facilitates Tbx20-dependent transcriptional repressionErin Kaltenbrun, Todd M Greco, Christopher E Slagle, et al.Development (Cambridge, England)|May 13, 2010
The BMP pathway acts to directly regulate Tbx20 in the developing heartElizabeth M Mandel, Erin Kaltenbrun, Thomas E Callis, et al.Nature Communications|June 9, 2017
Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistanceMoiez Ali, Erin Kaltenbrun, Gray R Anderson, et al.Elife|September 7, 2022
Genetically manipulating endogenous Kras levels and oncogenic mutations in vivo influences tissue patterning of murine tumorigenesisÖzgün Le Roux, Nicole L K Pershing, Erin Kaltenbrun, et al.Pageof 1